financetom
Business
financetom
/
Business
/
Virgin Australia posts "strong increase" in 1H profit, internal memo shows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Virgin Australia posts "strong increase" in 1H profit, internal memo shows
Mar 5, 2024 12:26 AM

(Reuters) - Virgin Australia, the carrier owned by Bain Capital, reported a profit of A$236 million ($153.2 million) in the first half of this fiscal year, reflecting a "strong increase" from last year, according to an internal memo seen by Reuters.

The carrier reported interim revenue of A$2.8 billion, citing a robust recovery in travel demand and an increase in profit margins to 8.5% in the six months ended December from 5% a year earlier.

U.S. private equity firm Bain Capital had aimed for a A$1 billion listing of Virgin on the Australian Securities Exchange, but the plans faced delays, Reuters reported last year.

The firm also cautioned of mounting challenges in the market ahead, while its larger rival Qantas posted a nearly 13% decline in first-half profit in February.

"The second half of the financial year will be tough with aggressive market pricing and strong capacity growth and we need to stay focussed on the execution of our plans," CEO Jayne Hrdlicka said in the memo. Hrdlicka had a few weeks ago announced her decision to step down as chief later this year.

Hrdlicka, who also serves as the chairman and board president of Tennis Australia, was the airline's first female CEO. However, she did not provide any further details on when she would depart from the airline.

She is one of the latest executive members to leave the carrier, following the resignation of Chief Development Officer David Marr in October, who had been overseeing the listing plans.

The potential listing would mark the largest new share sale on the Australian exchange in almost two years since GQG Partners raised A$1.18 billion in a 2021 debut.

Hrdlicka also noted that the carrier had made significant efforts to improve its services, "following what were clearly some challenging months in the lead up to Christmas."

($1 = 1.5406 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MAG Silver Files Preliminary Base Shelf Prospectus; Reported Q1 Earnings Earlier Tuesday
MAG Silver Files Preliminary Base Shelf Prospectus; Reported Q1 Earnings Earlier Tuesday
May 14, 2024
03:58 PM EDT, 05/14/2024 (MT Newswires) -- MAG Silver ( MAG ) , which earlier Tuesday reported first-quarter results, said shortly before the close of trade said filed a preliminary short form base shelf prospectus. According to the latest statement, the filing is with the securities commissions in all of the provinces and territories of Canada. A corresponding registration statement...
Vistra Unusual Options Activity For May 14
Vistra Unusual Options Activity For May 14
May 14, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Vistra ( VST ). Looking at options history for Vistra ( VST ) we detected 23 trades. If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 39% with bearish. From...
Dollar General May Miss First-Quarter Views, But Low Expectations Present Favorable Setup, UBS Says
Dollar General May Miss First-Quarter Views, But Low Expectations Present Favorable Setup, UBS Says
May 14, 2024
03:52 PM EDT, 05/14/2024 (MT Newswires) -- Dollar General ( DG ) may miss earnings and comparable sales expectations when it reports fiscal first-quarter results on May 30 but low expectations leading into the print offer a favorable setup, UBS Securities said on Tuesday. The brokerage reduced its earnings per share target to $1.50 from $1.55, putting it further below...
US FDA extends review of Ascendis Pharma's hormone disorder therapy
US FDA extends review of Ascendis Pharma's hormone disorder therapy
May 14, 2024
May 14 (Reuters) - The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's ( ASND ) therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday. U.S.-listed shares of the company were down 6.6% in late afternoon trading. The health regulator notified that data submitted for the ongoing review...
Copyright 2023-2026 - www.financetom.com All Rights Reserved